InvestorsHub Logo
Followers 44
Posts 2083
Boards Moderated 1
Alias Born 05/01/2018

Re: None

Thursday, 06/25/2020 1:35:58 PM

Thursday, June 25, 2020 1:35:58 PM

Post# of 363
Company Information
https://kitovpharma.investorroom.com/

Kitov Pharma is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare and business professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov’s flagship combination drug, Consensi™, achieved the primary efficacy endpoints for its Phase III and Phase III/IV clinical trials, and was approved by the U.S. FDA for patients suffering from osteoarthritis pain and hypertension. NT-219, which is developed by Kitov's majority-owned subsidiary, TyrNovo Ltd., is a novel patented small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development. By lowering development risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives.

"It never was my thinking that made the big money for me. It always was the sitting. Got that? My sitting tight!" - Reminiscences of a Stock Operator -